AR078786A1 - Derivados de la cromenona - Google Patents

Derivados de la cromenona

Info

Publication number
AR078786A1
AR078786A1 ARP100103937A AR078786A1 AR 078786 A1 AR078786 A1 AR 078786A1 AR P100103937 A ARP100103937 A AR P100103937A AR 078786 A1 AR078786 A1 AR 078786A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
halogen
independently selected
ring
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Bernand Christophe Barlaam
Van Der Brempt Christine Marie Paul Lambert
Remy Robert Morgentin
Sebastian Louis Degorce
Patrick Ple
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR078786A1 publication Critical patent/AR078786A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP100103937 2009-10-27 2010-10-26 Derivados de la cromenona AR078786A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09306017 2009-10-27

Publications (1)

Publication Number Publication Date
AR078786A1 true AR078786A1 (es) 2011-11-30

Family

ID=43085922

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103937 AR078786A1 (es) 2009-10-27 2010-10-26 Derivados de la cromenona

Country Status (41)

Country Link
US (5) US8399460B2 (oth)
EP (1) EP2493870B1 (oth)
JP (2) JP5657010B2 (oth)
KR (1) KR101738195B1 (oth)
CN (2) CN104447657B (oth)
AR (1) AR078786A1 (oth)
AU (1) AU2010311107B9 (oth)
BR (1) BR112012010124B8 (oth)
CA (1) CA2776994C (oth)
CL (1) CL2012001056A1 (oth)
CO (1) CO6541528A2 (oth)
CR (1) CR20120217A (oth)
CU (1) CU20120069A7 (oth)
CY (1) CY1116143T1 (oth)
DK (1) DK2493870T3 (oth)
DO (1) DOP2012000124A (oth)
EA (1) EA020523B9 (oth)
EC (1) ECSP12011838A (oth)
ES (1) ES2530943T3 (oth)
GT (1) GT201200126A (oth)
HN (1) HN2012000889A (oth)
HR (1) HRP20150146T1 (oth)
IL (1) IL219191A0 (oth)
IN (1) IN2012DN03328A (oth)
ME (1) ME02050B (oth)
MX (1) MX2012005027A (oth)
MY (1) MY179833A (oth)
NI (1) NI201200081A (oth)
NZ (1) NZ599457A (oth)
PE (1) PE20130149A1 (oth)
PH (1) PH12012500804A1 (oth)
PL (1) PL2493870T3 (oth)
PT (1) PT2493870E (oth)
RS (1) RS53813B1 (oth)
SA (1) SA110310808B1 (oth)
SI (1) SI2493870T1 (oth)
SM (1) SMT201500036B (oth)
TW (1) TWI483939B (oth)
UA (1) UA107474C2 (oth)
UY (1) UY32978A (oth)
WO (1) WO2011051704A1 (oth)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5599783B2 (ja) 2008-05-30 2014-10-01 アムジエン・インコーポレーテツド Pi3キナーゼの阻害薬
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
UY34013A (es) * 2011-04-13 2012-11-30 Astrazeneca Ab ?compuestos de cromenona con actividad anti-tumoral?.
MA38287B1 (fr) 2013-01-23 2018-08-31 Astrazeneca Ab Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer
AU2014224445C1 (en) * 2013-03-04 2017-07-27 Astrazeneca Ab Combination treatment
WO2015191745A1 (en) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
EP3154960A1 (en) 2014-06-13 2017-04-19 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
HK1231477A1 (zh) 2014-06-13 2017-12-22 吉利德科学公司 磷脂酰肌醇3-激酶抑制剂
CA2952018A1 (en) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors
KR20170012558A (ko) 2014-06-13 2017-02-02 길리애드 사이언시즈, 인코포레이티드 포스파티딜이노시톨 3-키나제 억제제
CN104803921A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种苯取代嘧啶衍生物的制备方法
CN104744376A (zh) * 2015-03-14 2015-07-01 长沙深橙生物科技有限公司 一种2-异丙基嘧啶衍生物的制备方法
KR101766731B1 (ko) 2015-06-23 2017-08-10 충남대학교산학협력단 강심 활성을 갖는 크로메논 유도체 및 이를 포함하는 심부전의 예방 또는 치료용 약학 조성물
US10526316B2 (en) * 2015-10-09 2020-01-07 Janssen Pharmaceutica Nv Quinoxaline and pyridopyrazine derivatives as PI3Kβ inhibitors
WO2018057808A1 (en) 2016-09-23 2018-03-29 Gilead Sciences, Inc. Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
AR121719A1 (es) * 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
KR20210141214A (ko) * 2020-05-15 2021-11-23 제이투에이치바이오텍 (주) 3원환 화합물 및 이의 의약 용도
US20240166617A1 (en) * 2021-02-01 2024-05-23 Geode Therapeutics Inc. Phosphoinositide 3 kinase beta inhibitors and compositions and methods thereof
US20230014445A1 (en) * 2021-05-03 2023-01-19 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
IL307950A (en) * 2021-05-03 2023-12-01 Petra Pharma Corp Allosteric chromanone inhibitors of PHOSPHOINOSITIDE 3-KINASE (PI3K) for the treatment of diseases
CN117597343A (zh) * 2021-05-03 2024-02-23 佩特拉制药公司 用于治疗疾病的磷酸肌醇3-激酶(pi3k)的变构色烯酮抑制剂
MX2023013987A (es) * 2021-05-27 2024-02-12 Petra Pharma Corp Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento contra el cáncer.
CN117769546A (zh) * 2021-05-27 2024-03-26 佩特拉制药公司 用于治疗疾病的磷酸肌醇3-激酶(pi3k)的变构色烯酮抑制剂
TW202329930A (zh) * 2021-09-30 2023-08-01 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑
US20250084048A1 (en) * 2021-10-07 2025-03-13 Relay Therapeutics, Inc. Pi3k-alpha inhibitors and methods of use thereof
US20250136568A1 (en) * 2021-12-08 2025-05-01 Nanjing Zenshine Pharmaceuticals Co., Ltd. Fused heterocyclic compounds as pi3kalpha inhibitors
WO2024003241A1 (en) 2022-06-30 2024-01-04 Astrazeneca Ab Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4
WO2024081904A1 (en) * 2022-10-14 2024-04-18 Genesis Therapeutics, Inc. Methods for treating cancer
TWI910755B (zh) * 2023-08-02 2026-01-01 大陸商鄭州同源康醫藥有限公司 稠環類化合物及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6027A (en) * 1849-01-09 Rotary blacksmith s twyer
WO1990006921A1 (en) 1988-12-21 1990-06-28 The Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
JPH05509302A (ja) 1990-06-20 1993-12-22 ジ・アップジョン・カンパニー 抗アテローム性動脈硬化性および抗血栓性1―ベンゾピラン―4―オン類および2―アミノ―1,3―ベンゾオキサジン―4―オン類
DE4318756A1 (de) 1993-06-05 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
US6291455B1 (en) 1996-03-05 2001-09-18 Zeneca Limited 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
SK288365B6 (sk) 1999-02-10 2016-07-01 Astrazeneca Ab Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy
EP1857443B1 (en) 2000-01-24 2012-03-28 AstraZeneca AB Therapeutic morpholino-substituted compounds
NZ522074A (en) 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
CN1255392C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管生成抑制剂的秋水仙醇衍生物
JP4646626B2 (ja) * 2002-08-16 2011-03-09 アストラゼネカ アクチボラグ ホスホイノシチド3−キナーゼβの阻害
AR054438A1 (es) * 2005-04-15 2007-06-27 Kudos Pharm Ltd Inhibidores de adn -pk
AU2006303037A1 (en) 2005-10-21 2007-04-26 Merz Pharma Gmbh & Co Kgaa Chromenones and their use as modulators of metabotropic glutamate receptors
SI2004654T1 (sl) * 2006-04-04 2013-11-29 The Regents Of The University Of California Pirazolopirimidinski derivati za uporabo kot kinazni antagonisti
WO2008064244A2 (en) 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
EP2112145A1 (en) 2008-04-24 2009-10-28 AxoGlia Therapeutics S.A. Chromenone derivatives useful for the treatment of neurodegenerative diseases
WO2010134082A1 (en) 2009-05-21 2010-11-25 Proteologics Ltd Chromenone derivatives for treatment of cancer
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives

Also Published As

Publication number Publication date
CY1116143T1 (el) 2017-02-08
EA201200618A1 (ru) 2012-12-28
US9029374B2 (en) 2015-05-12
CR20120217A (es) 2012-06-28
CN102712615B (zh) 2014-12-17
WO2011051704A1 (en) 2011-05-05
HK1174027A1 (en) 2013-05-31
US20130158026A1 (en) 2013-06-20
PT2493870E (pt) 2015-02-18
EA020523B1 (ru) 2014-11-28
JP5657010B2 (ja) 2015-01-21
KR20120098724A (ko) 2012-09-05
IN2012DN03328A (oth) 2015-10-23
HRP20150146T1 (hr) 2015-05-22
BR112012010124A2 (pt) 2016-06-07
CA2776994A1 (en) 2011-05-05
KR101738195B1 (ko) 2017-05-19
NZ599457A (en) 2014-04-30
US8673906B2 (en) 2014-03-18
ME02050B (me) 2015-05-20
JP2013508449A (ja) 2013-03-07
HN2012000889A (es) 2015-08-03
PH12012500804A1 (en) 2022-10-03
US9718800B2 (en) 2017-08-01
NI201200081A (es) 2012-11-07
MX2012005027A (es) 2012-09-07
CL2012001056A1 (es) 2012-10-05
BR112012010124B8 (pt) 2021-05-25
CO6541528A2 (es) 2012-10-16
SI2493870T1 (sl) 2015-03-31
HK1206335A1 (zh) 2016-01-08
DOP2012000124A (es) 2012-07-15
BR112012010124B1 (pt) 2021-02-17
UY32978A (es) 2011-05-31
ECSP12011838A (es) 2012-06-29
JP2015078202A (ja) 2015-04-23
EA020523B9 (ru) 2015-01-30
TWI483939B (zh) 2015-05-11
DK2493870T3 (en) 2015-02-23
AU2010311107A1 (en) 2012-05-03
US20160272607A1 (en) 2016-09-22
RS53813B1 (sr) 2015-06-30
IL219191A0 (en) 2012-06-28
US20160060240A1 (en) 2016-03-03
AU2010311107B9 (en) 2014-06-19
CA2776994C (en) 2017-10-31
US20140194419A1 (en) 2014-07-10
CN102712615A (zh) 2012-10-03
CN104447657B (zh) 2016-08-17
PE20130149A1 (es) 2013-03-10
ES2530943T3 (es) 2015-03-09
JP5872016B2 (ja) 2016-03-01
US8399460B2 (en) 2013-03-19
CN104447657A (zh) 2015-03-25
MY179833A (en) 2020-11-17
EP2493870A1 (en) 2012-09-05
AU2010311107B2 (en) 2014-03-27
UA107474C2 (uk) 2015-01-12
US20110098271A1 (en) 2011-04-28
SA110310808B1 (ar) 2013-11-24
TW201121960A (en) 2011-07-01
SMT201500036B (it) 2015-05-05
CU20120069A7 (es) 2012-10-15
PL2493870T3 (pl) 2015-04-30
EP2493870B1 (en) 2014-12-17
GT201200126A (es) 2014-03-03

Similar Documents

Publication Publication Date Title
AR078786A1 (es) Derivados de la cromenona
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen
UY28578A1 (es) Derivados de amida
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
AR067443A1 (es) Derivados heterociclicos de n-benziloxazolidinonas potenciadores de receptores de glutamato mglur2, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de trastornos del sistema nervioso central
AR045529A1 (es) Imidazoquinolinas sustituidas con grupos ariloxi o arilalquilenoxi
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
AR073406A1 (es) Aminodihidrotiazinas fusionadas con tetrahidropiranos,inhibidoras de bace1 y de la produccion de abeta amiloide, composiciones farmaceuticas que las contienen y usos de las mismas para el tratamiento de enfermedades neurodegenerativas,tales como alzheimer.
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
AR058703A1 (es) Triazolopiridazinas inhibidoras de tirosinquinasas, metodo de preparacion, composiciones farmaceuticas que las contienen y usos terapeuticos en el tratamiento del cancer
AR054035A1 (es) Derivados benzodioxano y benzodioxolano y uso de los mismos
PE20190337A1 (es) NUEVOS DERIVADOS DE PIRROLO [2,3-d]PIRIMIDA, UN PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
AR054799A1 (es) Derivados de oxindol
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
AR056511A1 (es) Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4
AR058287A1 (es) Derivados de isoquinolina y composicion farmaceutica
AR080074A1 (es) Naftiridinas sustituidas y su uso como medicamentos
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
AR073043A1 (es) Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras.
AR063147A1 (es) Compuestos heterociclicos nitrogenados inhibidores de receptores de histamina h3, metodo de preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de trastornos del sistema nervioso central.
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
AR061015A1 (es) Compuesto y composicion farmaceutica para el tratamiento de un trastorno del sistema nervioso central relacionado con o afectado por el receptor histamina-3 y para la inhibicion del receptor h3 y proceso para la preparacion del compuesto
UY26048A1 (es) Derivados de piridopiranoacepinas, su preparacion y su aplicacion terapeutica
AR069813A1 (es) Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento

Legal Events

Date Code Title Description
FG Grant, registration